New York-based Mantis Biotech is developing 'digital twins' of human anatomy to fill data gaps in genomics and clinical research. These physics-based models simulate real-world scenarios, from predicting sports injuries to accelerating drug discovery.

By integrating diverse data sources—textbooks, motion capture, medical imaging—the platform generates synthetic datasets that enhance the understanding of rare diseases and unusual conditions where reliable data is scarce. This innovation promises a transformation in how we approach biomedical research and clinical documentation.

Mantis Biotech's founder Georgia Witchel envisions these digital twins as indispensable tools for training surgical robots, optimizing patient care, and even predicting patterns of human behavior. The platform’s ability to generate realistic models from limited data is particularly revolutionary in edge cases where standard datasets are insufficient.

The technology has already seen success in professional sports, with an NBA team among its clients. However, the broader application across pharmaceutical labs and FDA trials highlights Mantis' ambition to democratize access to comprehensive medical insights.

Witchel’s vision is ambitious: a world where digital twins are as commonplace as 3D models today. Yet, she acknowledges the ethical considerations around data exploitation, suggesting a mindset shift towards virtual human testing in medicine.